Image source: Getty Images
Since selling Legal & General a couple of months ago, I’ve been searching for a new income stock. While I see a handful of potential candidates, there are some I’m keen to avoid.
Here are three of them from the FTSE 100.
A clear guide to Anthropic’s IPO (without the hype)
A new free report just landed on Anthropic – and we’ve written it for investors who want the facts, not the noise.
We break down what matters most for the IPO question: could it be a genuine potential opportunity… or is it all baseless hype?
There’s no jargon. No hard sell. Just a straightforward read that you can see immediately.
Blockbuster yield
The first dividend stock is Ithaca Energy (LSE:ITH). This UK-focused oil and gas producer sports the highest dividend yield in the index — an eye-popping 9.5% for 2026!
What’s not to like? Well, for starters, I have no idea where energy prices will land next year. But with the Iran war supposedly over, there’s a good chance that oil prices won’t be revisiting this year’s highs.
On the other hand, Ithaca does have oil and gas hedges extending into 2028. So next year’s payout looks safe, as things stand. The firm allocates 30% of its post-tax operating cash flow to dividends.
Plus, there could soon be a regulatory approval of the Rosebank oil field in the UK North Sea, in which Ithaca has a 20% interest. That’s a significant potential growth project.
Then again, there’s no guarantee it will be approved, with up to 100 (mainly Labour) MPs reportedly ready to oppose the development. The energy secretary is minded to reject it, according to The Guardian.
Due to all the uncertainty, this isn’t a stock that interests me, despite the blockbuster yield.
Sluggish sales, low yield
Haleon (LSE:HLN) is another Footsie share I’m steering clear of. This is the consumer healthcare company that owns brands like Sensodyne, Panadol and Beechams.
Now, it could be argued this isn’t much of a dividend stock because it’s only yielding 2.1%. But this is the problem. For a company in a very mature market growing revenue at just 2.5% per year, I would want a significantly higher yield than that.
In Q3, organic revenue growth of 2.6% was below expectations, due to softness in categories like cough, cold and flu consumption. Expected full-year revenue growth of around 2.5% is below the medium-term target of 4%-6%.
Of course, the defensive nature of the stock will appeal to some investors. And there was strong growth in emerging markets in the quarter, led by India with high-teens growth. So there’s certainly nothing fundamentally wrong with the business.
However, due to a combination of low revenue growth and a modest yield, this is another stock that doesn’t interest me.
Healthcare plodder
Finally, GSK (LSE:GSK) is another I’ve long found underwhelming. It has a nasty habit of underperforming the FTSE 100, while offering a so-so dividend yield of 3.7%. That’s not much higher than the index average.
Beyond income, I find it hard to buy into the growth story, with key patents on its HIV franchise beginning to expire before 2029. GSK has set a target of reaching over £40bn in revenue by 2031, up from £32.7bn last year. But investors are yet to be convinced.
The key attraction here is a cheap valuation, with GSK trading at just 9.8 times next year’s forecast earnings. If it can reach its 2031 targets, there could be solid gains to be had here (dividends and share price).
Again though, I find this dividend stock underwhelming. I much prefer this one yielding almost 7%…
What income stock do we like better than GSK right now?
One of our Share Advisor analysts has just released a brand new stock report that we think is a must-read for any investor looking to try and generate potential income.
And the best bit is that you can see if for yourself, right now, absolutely free of charge!
No jargon. No hard sell. Just a clear look at an income share we think is worth your time.
Â
Ben McPoland has no position in any of the companies mentioned.








